Ocular Therapeutix, Inc. OCUL
Set alert
6.73 USD -0.24 -3.44%
At close
6.80 +0.07 +1.04%
Pre-market · Nov 3, 4:42 AM ET
6.58 Day range 7.03
6.00 52-week range 16.44
- YTD
- -44.56%
- 1 year
- -42.28%
- Open
- 6.97
- Prev close
- 6.97
- Mkt cap
- 1.48B
- Vol
- 1.88M
- Avg vol
- 3.06M
- EPS
- -1.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.58
- High
- 7.03
- Forward P/E
- -4.55
- Beta
- 1.22
- Short ratio
- 7.60
- Inst. own
- 95.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.81
- 200-d avg
- 9.12
- 1y target
- 25.45
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.45 +278.2% upside
Now 6.73
- Target (low)
- 14.00
- Target (mean)
- 25.45
- Target (high)
- 34.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3548 | -0.37 – -0.30 | -0.38 | +6.6% | 14.30M | -1.7% | 6 |
| Next quarter | -0.37776 | -0.43 – -0.31 | -0.29 | -30.3% | 14.18M | +7.0% | 6 |
| Current year | -1.44 | -1.54 – -1.18 | -1.42 | -1.7% | 52.84M | +1.7% | 5 |
| Next year | -1.48 | -1.86 – -1.09 | -1.44 | -2.5% | 102.04M | +93.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Needham | Reiterated | Buy | Buy |
| Oct 12, 2026 | UBS | Initiated | — | Buy |
| Oct 2, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Sep 29, 2026 | Needham | Reiterated | Buy | Buy |
| Sep 16, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Sep 16, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 4, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jun 25, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jun 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 18, 2026 | Baird | Maintained | Outperform | Outperform |
| May 6, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| May 5, 2026 | Needham | Reiterated | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 3, 2026 | Clear Street | Maintained | Buy | Buy |
| Feb 20, 2026 | Needham | Maintained | Buy | Buy |
| Feb 18, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Dec 9, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Dec 8, 2025 | Needham | Reiterated | Buy | Buy |
| Dec 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 25, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 5, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Oct 30, 2025 | TD Cowen | Maintained | Buy | Buy |
| Oct 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 3, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 3, 2025 | Baird | Maintained | Outperform | Outperform |
| Oct 2, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Oct 1, 2025 | Needham | Maintained | Buy | Buy |
| Oct 1, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Sep 15, 2025 | Chardan Capital | Initiated | — | Buy |
| Aug 6, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
